CollPlant Biotechnologies Future Growth
Future criteria checks 2/6
CollPlant Biotechnologies is forecast to grow earnings and revenue by 64.7% and 41.2% per annum respectively while EPS is expected to grow by 69.4% per annum.
Key information
64.7%
Earnings growth rate
69.4%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 41.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Nov 2024 |
Recent future growth updates
Recent updates
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow
Aug 20
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow
Feb 03Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?
Nov 02CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business
Sep 06Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Jul 14Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Mar 02Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth
Nov 10CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M
Aug 25We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth
Jul 22CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 22CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company
Aug 05Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation
Jul 29The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business
Jun 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 20 | 0 | 1 | 1 | 2 |
| 12/31/2025 | 13 | -6 | -6 | -6 | 2 |
| 12/31/2024 | 0 | -17 | -17 | -16 | 1 |
| 9/30/2024 | 1 | -17 | -14 | -13 | N/A |
| 6/30/2024 | 1 | -17 | -4 | -3 | N/A |
| 3/31/2024 | 11 | -7 | -3 | -3 | N/A |
| 12/31/2023 | 11 | -7 | -4 | -3 | N/A |
| 9/30/2023 | 11 | -7 | -5 | -4 | N/A |
| 6/30/2023 | 11 | -7 | -15 | -14 | N/A |
| 3/31/2023 | 1 | -17 | -15 | -14 | N/A |
| 12/31/2022 | 0 | -17 | -15 | -14 | N/A |
| 9/30/2022 | 1 | -16 | -14 | -13 | N/A |
| 6/30/2022 | 1 | -15 | -14 | -12 | N/A |
| 3/31/2022 | 1 | -14 | -14 | -12 | N/A |
| 12/31/2021 | 16 | 0 | 1 | 3 | N/A |
| 9/30/2021 | 16 | 1 | 2 | 3 | N/A |
| 6/30/2021 | 20 | 5 | 7 | 8 | N/A |
| 3/31/2021 | 20 | 6 | 9 | 9 | N/A |
| 12/31/2020 | 6 | -6 | -5 | -4 | N/A |
| 9/30/2020 | 6 | -7 | -5 | -4 | N/A |
| 6/30/2020 | 3 | -11 | -8 | -7 | N/A |
| 3/31/2020 | 2 | -11 | -8 | -7 | N/A |
| 12/31/2019 | 2 | -11 | -7 | -6 | N/A |
| 9/30/2019 | 6 | -6 | -2 | -1 | N/A |
| 6/30/2019 | 6 | -6 | -2 | -1 | N/A |
| 3/31/2019 | 5 | -4 | -2 | -1 | N/A |
| 12/31/2018 | 5 | -6 | -2 | -1 | N/A |
| 9/30/2018 | 1 | -6 | -7 | -6 | N/A |
| 6/30/2018 | 1 | -6 | N/A | -6 | N/A |
| 3/31/2018 | 1 | -7 | N/A | -5 | N/A |
| 12/31/2017 | 0 | -6 | N/A | -5 | N/A |
| 9/30/2017 | 0 | -6 | N/A | -5 | N/A |
| 6/30/2017 | 0 | -7 | N/A | -5 | N/A |
| 3/31/2017 | 0 | -7 | N/A | -5 | N/A |
| 12/31/2016 | 0 | -7 | N/A | -5 | N/A |
| 9/30/2016 | 0 | -7 | N/A | -5 | N/A |
| 6/30/2016 | N/A | -7 | N/A | -5 | N/A |
| 3/31/2016 | N/A | -6 | N/A | -5 | N/A |
| 12/31/2015 | N/A | -5 | N/A | -4 | N/A |
| 9/30/2015 | N/A | -4 | N/A | -4 | N/A |
| 6/30/2015 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2015 | N/A | -3 | N/A | -3 | N/A |
| 12/31/2014 | N/A | -3 | N/A | -3 | N/A |
| 9/30/2014 | N/A | -4 | N/A | -4 | N/A |
| 6/30/2014 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2014 | N/A | -4 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLGN's revenue (41.2% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: CLGN's revenue (41.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLGN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 20:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CollPlant Biotechnologies Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Linda Pomeroy | Edison Investment Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |